ARTL Valuation

Artelo Biosciences Inc

Add to Watchlist

Advanced Chart

14.170

-0.38(-2.612%)1D

Overview
Forecast
Valuation
Earnings

ARTL Relative Valuation

ARTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARTL is overvalued; if below, it's undervalued.

Historical Valuation

Artelo Biosciences Inc (ARTL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.38. The fair price of Artelo Biosciences Inc (ARTL) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：13.74

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

12.20

P/B

Median3y

0.97

Median5y

1.15

-68.53

FCF Yield

Median3y

-172.51

Median5y

-120.22

Competitors Valuation Multiple

The average P/S ratio for ARTL's competitors is 3.24, providing a benchmark for relative valuation. Artelo Biosciences Inc Corp (ARTL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARTL.O

Artelo Biosciences Inc

Loss

Average P/S: 3.24

9.98M